AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Anish Suri, Ph.D., president & chief scientific officer (CSO) of Cue Biopharma, to transition to principal research and immunology advisor BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.

Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently serving as Vice President of U.S. Immunology. In this capacity, Mr. Stenhouse oversaw U.S. sales and marketing teams for ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...